Because CT antigens are useful targets for cancer vaccination and immunotherapy through the activation of cytotoxic T lymphocytes [26], LEMD1 may be a useful candidate for molecular targeted therapy for OSCC. The gene discussed is LEMD1; the disease is cancer.